Simufilam Slowed Cognitive Decline in a Randomized Withdrawal Trial of Mild-to-Moderate Alzheimer’s Disease
- Pharmacology/BS
- · 2023. 7. 6.
Suono Bio Reports Encouraging Results From a First in Human (FiH) Study of Its Ultrasound Mediated Drug Delivery Platform In a recent study, Suono Bio Inc. has unveiled promising findings from its first clinical trial testing the SuonoCalm™ platform. This groundbreaking study demonstrates the feasibility and safety of using ultrasound for drug delivery in the gastrointestinal tract. The study co..
Plus Therapeutics, a clinical-stage pharmaceutical company, announced positive interim updates from its ReSPECT™ clinical trials at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) Annual Meeting. The ReSPECT-GBM Phase 1 trial showed safety and overall survival correlation with absorbed radiation dose in recurrent glioblastoma patients. The ReSPECT-LM Phase 1/Part A trial demonstrated..
SK bioscience and Sanofi have announced positive results from the Phase II study of their 21-valent pneumococcal conjugate vaccine candidate, GBP410 (also known as SP0202). The vaccine demonstrated positive safety and immunogenicity data in infants. The companies plan to start Phase III trials in the first half of 2024. The Phase II clinical trial evaluated the safety and immunogenicity of GBP41..
Delta-Fly Pharma Inc. has announced the schedule for the interim analysis of the Phase 3 study of DFP-10917 in relapsed/refractory acute myeloid leukemia (R/R AML) patients. The interim analysis will be based on outcome measurements including complete remission rate, overall survival, and safety. The first data processing is scheduled to be completed in mid-July 2023, followed by the second data..
First Wave BioPharma, a clinical-stage biopharmaceutical company specializing in gastrointestinal (GI) diseases, has announced that the final patient has been dosed in the Phase 2 SPAN clinical trial. The trial is investigating an enhanced enteric microgranule delivery formulation of adrulipase for the treatment of exocrine pancreatic insufficiency (EPI) in cystic fibrosis (CF) patients. Topline..
First Wave BioPharma, a clinical-stage biopharmaceutical company specializing in gastrointestinal (GI) diseases, has announced the publication of two patent applications for its enhanced enteric microgranule delivery formulation of adrulipase. The patents cover composition of matter and methods of use claims and were published by both the United States Patent and Trademark Office (USPTO) and the..